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Purpose: The purpose of this study is to identify a prospective association between CA125 and tumorigenic
ovarian cancer cells, using the new method of orthotopic transplantation (1).
Method: After making the surgical ovarian cancer specimen into cell suspension, we separated the tumorigenic
cells from the nontumorigenic cancer cells based on cell surface marker (cancer antigen CA125 and lineage
markers) expression. We developed a SCID mice model in which the CA125+/ lineage- and CA125-/ lineage- cells
were injected into ovarian parenchyma by use of a microinjector. As a measure of effectiveness of tumor-forming,
tumor weight, abdominal distension, ascites volume and activity, subcutaneous fat were determined or observed.
Immunohistochemistry was done to determine tumor cell markers.
Results: We found that the cells of CA125+/ lineage- were able to form new tumors; whereas, an equal quantity
of CA125-/lineage- cells failed to form any tumors. The new generated tumor contained additional CA125-/
lineage- tumorigenic cells as well as the phenotypically diverse population of nontumorigenic cells. Quantities
were judged to be significantly different P < 0.0001.
Conclusion: CA125+/ lineage- cells, which may be ovarian cancer stem cells, were the source for tumor recurrence.
The strategies designed to target this cell population may lead to more effective therapies.
Keywords: Ovarian cancer, CA125, Tumor stem cellOvarian cancer is the fifth most common cause of can-
cer death in women and is the most common cause of
death by a gynecological tumor [1], where the recur-
rence and drug resistance are the focus and difficulty of
the treatment. As early as 1977, Hamburger et al. found
that only a portion of the ovarian cancer cells may be
cultured in vitro or in vivo to generate colonies, and
they proposed that tumor stem cells might be found in
the solid tumors [2]. These cells are not sensitive to
chemotherapy and radiotherapy and are the “seed cells”
for tumor recurrence and metastasis. This is the main
target of our therapy. However, due to lack of informa-
tion about the abnormal expression spectra of mem-
brane protein of the tumor stem cells and the phenotype
of normal stem cells in ovarian cancer, one can only
isolate and identify the ovarian cancer stem cells by* Correspondence: zhanghui98765@163.com
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unless otherwise stated.screening stem cell markers associated with the epithe-
lial stem cells that lie on the surface of the ovarian cells.
In this study, our goal was to apply the orthotopic
transplantation mode to preliminarily identify an associ-
ation between the tumor marker CA125 and ovarian
tumor stem cells [3]. Tumor antigen CA125 is a classical
marker for early diagnosis and recurrence of ovarian
cancer [4,5], where its value is positively correlated with
the degree of tumor malignancy and the possibility of
recurrence. Our experiment’s design was based on the
phenotypic stability of the tumor stem cells [6]. Using
flow cytometry, the primary cancer cells were divided
into CA125+/lineage-group and CA125-/lineage-group.
The in vivo tumorigenicity of these two groups were ob-
served and satisfactory results were obtained.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Materials
Mice
A total of 40 female SCID (Severe combined immuno-
deficiency) mice of 6 to 8 weeks old was purchased from
Shanghai SLRC Laboratory Animal Center (NO. 0014393
and NO. 0015117). Their weight ranged from 15 g to 18 g.
1 week later, they received intraperitoneal injection of
Etoposide (10 mg/kg dose, diluted into 200 ml with HBSS,
Hank’s balanced salt solution), and meanwhile received a
small piece of Estrogen sustained release tablet in the
hypoderm of the neck, which was placed through trocar
and was to lower the immunity and shorten the period of
neoplasia. And 6 days later, they were inoculated with cell
suspension under 4% Chloral Hydrate (0.1 ml/g dose)
anesthesia. The animal experiments were approved by the
animal care and use committee in HeBei University.
Cells
Human ovarian cancer specimens were obtained within
1 hour of surgical resection (frozen disease results in
epithelial ovarian carcinoma) and placed in cellular sus-
pension under aseptic conditions. Patients were diagnosed
as ovarian cancer by preoperative CT scan. This study was
approved by the ethics committee and patients signed in-
formed consent.
Reagents
The first antibody OC125 (ab1107) was purchased from
Abcam company. The second antibody labeled by allophy-
cocyanin (APC) was purchased from Unitech Company.
Anti-CD140b labeled by phycoerythrin (PE phycoerythrin
28D4) was purchased from American Pharmingen Com-
pany. The Fluorescein isothiocyanate (FITC)-labeled anti-
CD31 (11–0319) and FITC-labeled anti-mouse class I
major histocompatibility complex (MHC) antibody (11–
5998, H-2Kd/H-2Dd) were purchased from American
eBioscience Company. FITC-labeled lineage-specific anti-
bodies (340546; CD3, CD16, CD19, CD20, CD14, CD56)
were purchased from American BD Company. Fetal bo-
vine serum, trypsin and EDTA were purchased from
American GIBCO Company. And the Metrigel was pur-
chased from American BD Biosciences Company. PI dye
was awarded by Institute of Pharmaceutical Technology
of the First Affiliated Hospital of Guangzhou Medical
College, and other analytical reagents were purchased
from GuangzhouWeiJia Technology Limited.
Instruments
Flow cell sorter (BECKMAN) (Beckman Coulter, Inc.
American), Flow cytometry (for cells detection of BD
FACS Ariat™) (BD Biosciences, American), Centrifuge
machine (Anke TDL-40B), superspeed refrigerated centri-




A total of 40 SCID mice were raised in the SPF (specific
pathogen free) laboratory of Zhongshan Ophthalmic
Hospital Center and the animal occupancy permit num-
ber was SKXY Guangdong 2005–0058. Mice were anes-
thetized with 4% chloral hydrate (0.1 mL/1 g).
Preparation of vaccinated primary tumor cell suspension
The fresh human ovarian cancer specimens were cut
into small blocks under aseptic conditions and applied with
pancreatin containing 0.02% ethylene diamine tetra-acetic
acid (EDTA) and incubated at 37°C for 15–20 min, while
blown with a 10 mL straw every 3–4 min to mix the tissue
blocks and pancreatin thoroughly. After that DMEM con-
taining 20% fetal bovine serum was added to stop diges-
tion, the cells were rinsed twice with HBSS, and filtered
with a 200 wells filter. Next, the tissues were collected and
applied with mixture of HBSS and matrigel (1:1).
Antibody labeling and flow sorting
After conducting cell counting, cells were placed into a
5 mL tube, and rinsed with HBSS containing 2% heat
inactivated calf serum(HICS)3 times; each rinse lasted for
5 min with a centrifugal speed of 350 g at 4°C and light-
proof. Then applied with 100 uL HBSS (106 cells/100 μL)
containing 2% HICS. First antibodies such as PI, lineage-
specific antibodies, CD140b, CD31, and OC125 were
added with a dilute concentration of 106cells/2 μL, incu-
bated at 4°C and light-proof conditions for 1 h, rinsed with
HBSS containing 2% HICS twice, followed by suspension
with 100 μL HBSS/2% HICS (106 cells /100 μL) and ap-
plied with 1–4 μL second antibody (anti-OC125) and
incubated at 4°C and light-proof conditions for another
1 h, rinsed with HBSS/2% HICS twice and suspended
with 1 mL HBSS/2% HICS. Antibodies, including first
the antibodies OC125 and APC-labeled (red) second
antibody, were used for labeling CA125 tumor cells, and
PE-labeled (orange color) anti-CD140b was used to
eliminate normal epithelial cells. FITC-labeled (green
light) anti-CD31 was used to eliminate blood platelets,
myelomonocytic and lymphocytes. The FITC-labeled
lineage-specific antibodies included anti-CD2, −CD3
-CD10, −CD16, −CD14, −CD18, −CD19, −CD64. Anti-
bodies with unspecified manufacturer were purchased
from PharMingen Company and they were marked dir-
ectly or indirectly with different fluorescence to facilitate
the sorting. Among the lineage-specific antibodies (anti-
CD2, −CD3 -CD10, −CD16, −CD14, −CD18, −CD19,
−CD64, -CD140b, CD31), CD2 and CD3 were used for
inhibiting T-lymphocytes reaction, CD10 and CD19 for
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CD18 for granulocyte, CD31 for blood platelet, myelomo-
nocyte and lymphocyte, CD64 for neutrophil granulocyte,
CD140b for human normal fibroblasts, smooth muscle
cells, glial cells, and chondrocytes. PI (Spontaneous red
fluorescence, can be isolated from the APC) was used to
label dead cells. A flow cell sorter (BECKMAN) was used
for cell sorting, where forward scatting and side scattering
were applied to remove overlapping cells. In the sorting
process, cells labeled by green, orange, and spontaneous
fluorescence were removed, while the red labeled cells
were expressions of the CA125+/lineage-ovarian cancer
cells and the remaining were CA125-/lineage-ovarian can-
cer cells.Animal vaccination
A total of 1.52 × 105 CA125+/lineage-cells and 11.1 ×
105 CA125-/lineage-cells were obtained. Negative cells
were conducted with negative gradient dilution, of
which 1.52 × 105 cells were selected and the rest were
discarded, and the selected cells were re-suspended with
fetal bovine serum/Matrige (1:1). A total of 40 SCID
mice was randomly divided into 4 groups: positive group
(A and B groups), negative group (A and B groups), ex-
perimental control group and blank control group, each
containing 10 mice. The positive group was vaccinated
with CA125+/lineager-cells, of which A group (5 mice)
and B group (5 mice) were vaccinated with 2 × 104 and
1 × 104 cells, respectively, with a vaccination dose of
10 μL each. The experimental control group was vacci-
nated with10 μL fetal bovine serum (1:1) and nothing
was applied in the blank control group. All the mice
were raised under the same conditions. The vaccination
methods referred to reference [3], and were illustrated
in Figure 1.Figure 1 Data when mice were injected with cell suspension.Animal observation
Each mouse was labeled with a random number accord-
ing to a random table prior to vaccination and weighted
every week. Every week, palpation was conducted in
mice at the vaccination site, and the reduction of sub-
cutaneous fat, touchable abdominal mass, abdominal
bloating, rounded protuberance, activity reduction and
other signs associated with tumor development were
visually observed. About 3 months later, mice began to
become thin and appeared to have reduced their phys-
ical activity. Six months later, the mice were executed by
breaking their necks; bilateral ovaries and related organs
were harvested and their abdominal cavities were dis-
sected for to determine metastasis. The weight growth
curve of mice are shown in Figure 2. Group A was positive
group. Group B was negative group. Group C was the ex-
perimental control group. Group D was the control group.
Group A B C curves first increased and then decreased,
especially the curve of group A decreased significantly in
the 5th month. Group D curve had been a growing trend.
Pathology test
After 6-months of observation, the vaccinated ovary and
the contralateral ovary of each mouse were cut into 2
parts, of which one part was fixed with 4% neutral formal-
dehyde liquid, followed by paraffin-embedded, general
slice and H&E staining, as well as immunohistochemistry
for detecting the CA125 expression (first antibody dilu-
tion: 1:50, second antibody dilution: 1:100, second anti-
body was the mouse monoclonal antibody against human
ovarian cancer antigen (CA125), and OC125). The other
part conducted with frozen section and labeled with fluor-
escent antibody: indirect APC-labeled mouse anti-human
CA125, and FITC-labeled anti-mouse I type MHC mo-
lecular, or H-2Kd/H-2Dd (first antibody dilution: 1:50,
second antibody dilution: 1:100, second antibody was the
mouse monoclonal antibody against human ovarian can-
cer antigen (CA125) and OC125 without nucleus stain-
ing). A confocal laser scanning microscopy was used to
observe the staining results and electronic microscopy
was used to observe the morphology of tumor cells.
Statistical analysis
SAS software was used for statistical analysis. Single vari-
ance analysis and LSD/t test was used to calculate P values
within each group and between the groups, where P <
0.0001 was considered statistically significant.
Results
Sorting results by flow cytometry
In Figure 3, the window of A contained live tumor cells
to be sorted, and cells in B window were obtained from
A window, which were FITC-negative and PE-negative
cells. Cells in window of C were obtained from B window,
Figure 2 The growth curve of four groups of mice weight.
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zontal line were FITC-, PE- and CA125- negative cells,
while cells outside the window or on the right of the hori-
zontal line were FITC-negative, PE-negative and CA125-
positive cells. Plots in D, E and F were testing results of
sorted negative cells. Compared with A window, dead cells
and cell debris in D window significantly reduced. Cells in
E window were obtained from D window, which detected
the purity of FITC- and PE-negative cells, while cells in F
window were obtained from D window, which detected
purity of FITC-, PE- and CA125-negative cells.
Tumorigenesis of vaccinated ovary
As seen in data presented in Table 1, 8 tumors were found
in the positive group. As shown in the follow Figures, no
tumor was observed in the negative and control groups.Figure 3 The flow cytometry test results of primary tumor cells after
live tumor cells to be sorted, and cells in B window were obtained from A
window of C were obtained from B window, where cells inside the windo
negative cells, while cells outside the window or on the right of the horizo
Plots in D, E and F were testing results of sorted negative cells. Compared
reduced. Cells in E window were obtained from D window, which detecte
were obtained from D window, which detected purity of FITC-, PE- and CATumorigenic status were showed in Figures 4, 5. Figure 4
is the state of pre-anatomy after tumor formation, Figure 5
is the state after anatomy. Figure 6 illustrated the ovarian
tumor on H&E staining of the vaccinated tumor cells
(×40). One case had peritoneal metastasis (Figure 7).
Figures 8 and 9 showed the immunohistochemical stain-
ing of the ovarian tumor for detecting expression of
CA125 (brown color). Two cases had liver metastasis,
as shown in Figures 10 and 11. Figure 11 was the tumor
transferred to liver under the electron microscopy, where
a tumor cell was at the upper right, and a solid nucleus
liver cell was found at the left bottom. Two cases had pel-
vic muscle metastasis, (Figure 12). Figure 13 showed the
expressions of human CA125 (red light) and mouse
antigen (green light) of the ovarian tumor. Analysis by
SAS FREQ showed that the difference among thedifferent fluorescent antibody labeling. The window of A contained
window, which were FITC-negative and PE-negative cells. Cells in
w or on the left of the horizontal line were FITC-, PE- and CA125-
ntal line were FITC-negative, PE-negative and CA125-positive cells.
with A window, dead cells and cell debris in D window significantly
d the purity of FITC- and PE-negative cells, while cells in F window
125-negative cells.
Table 1 Tumor number and vaccination number in study
mice












Blank control group 0/10
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was not significant, P=0.4444. The difference between
CA125+ /lineage-group and CA125- /lineage-group was
statistically significant, (P<0.0001) While the difference
between CA125+ /lineage-group and the control group
(blank control and control groups) was significant
(P<0.0001), and the difference between CA125-/lineage-
group and the control group was not significant.
Discussion
Ovarian cancer is characterized by insidious onset, rapid
progression, and lack of effective early diagnosis; ap-
proximately 70% patients are diagnosed in the advanced
stages of the disease, and when remission is achieved,Figure 4 The state after anatomy after tumor formation.
Figure 5 The state of pre-anatomy after tumor formation.
Figure 6 The ovarian tumor on H&E staining of the vaccinated
tumor cells (×40).
Figure 7 A case had peritoneal metastasis. Figure 9 The immunohistochemical staining of the ovarian
tumor for detecting expression of CA125 (brown color).
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significant progress of surgery and chemotherapy has
been achieved in recent years, the 5-year survival rate in
advanced ovarian cancer is still hovering at 20% to 30%.
Efforts have been focused on finding new and more ef-
fective means to improve the prognosis for patients diag-
nosed with ovarian cancer.
Theory of tumor stem cell believes that tumor stem
cells account for 0.01% ~ 0.1% of the total number of
tumor cells with unlimited proliferative potential. They
can proliferate by means of symmetric and asymmetric
splits, so as to generate new tumor stem cells, initial
tumor cells, initial tumor stem cells, and tumor precursor
cells, etc. [7,8]. The current methods of treating tumors
are focused on most cells in the tumor tissue, rather than
only the tumor stem cells. Therefore, though the tumor
tissues fade after surgical resection or chemotherapy, the
remaining stem cells will generate tumors again, resulting
in tumor recurrence and metastasis. Thus, finding the
specific biological characteristics of tumor stem cells may
enable targeting or selective killing tumor stem cells, pre-
vent tumor recurrence, and metastasis.Figure 8 The immunohistochemical staining of the ovarian
tumor for detecting expression of CA125 (brown color).Traditionally, it was believed that ovarian cancer was
caused by menstruation-induced periodic destruction of
epithelial tissues resulting in tumorigenesis. Recent patho-
logical studies have found that many ovarian cancers
occur in the distal oviduct and even in the injured location
of the endometria [9,10]. However, the above method is
disputed since the exact origin of ovarian cancer is still un-
clear as yet. Ovarian tumor stem cells are believed to be
the root cause of ovarian cancer recurrence. However, spe-
cific markers of ovarian tumor stem cells have not been
unified. Currently, common known markers are CD133,
Nestin, CD24, CD166 and CD44 [11-13]. However, due to
lack of information about the abnormal expression spectra
of membrane protein of the tumor stem cells and pheno-
type of normal stem cells in ovarian cancer, one can only
isolate and identify the ovarian cancer stem cells by
screening cell markers associated with the epithelial stem
cells on the ovarian surface. Treatment of the selective
targeting stem cells is still in its infant stage, since it is
still unclear how many markers there are for tumor
stem cells [14]. It is necessary to find out more specific
markers and explore their physiological functions, thus
to achieve better understanding of the differentiation
process from multipotent stem cells to tissues at differ-
ent stages, and applied these as a new targeting anti-
cancer therapy [15,16].
CA125, found in 1981, is an inhomogeneous, high mo-
lecular weight mucin-like glucoprotein. Bast [17,18] ap-
plied ovarian serous cystadenocarcinoma serial OVCA443
to BALB/c mice and purified with myeloma to obtain a
monoclonal antibody, named OC125, and its correspond-
ing antigen was named CA125. CA125 is located in the
cavity epithelial cells during the embryonic development
process, and disappears in the first few hours after birth,
but appears again in ovarian cancer cells [19,20]. In recent
years, many studies have been conducted to investigate
the relation of CA125 quality in the body fluids and its oc-
currence, clinical staging, and histological type of systemic
Figure 11 The SEM results of liver metastases.
Figure 12 The pelvic muscle metastasis.
Figure 10 Liver metastasis.
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has been found that [21] the involving risk of ovarian can-
cer in healthy population with serum CA125 > 30 U/mL
was significantly increased and it was positively correlated
with the concentration in the blood. For menopause
women without symptoms, the incidence of CA125 eleva-
tion to ovarian cancer significantly increases. With the
progress of ovarian cancer, increase in clinical stages and
the occurrence of tumor metastasis (disease aggravating),
the serum CA125 concentration gradually increases which
is positively correlated with number of tumor cells. In pa-
tients with effective surgical treatment and chemotherapy,
the CA125 quickly decrease. In cases of recurrence and
drug resistance, the CA125 elevation appears prior to the
clinical symptoms, indicating CA125 is an early markerfor recurrence and drug resistance, which is similar to the
characteristics of the tumor stem cells. However, no re-
ports have been found to reveal the relationships be-
tween them. Is the CA125 another marker for ovarian
tumor stem cells? In this study, we aimed to explore the
relationship between CA125 and ovarian tumor stem
cells, and applied CA125 as a surface marker, then
sorted tumor stem cells quickly and effectively by using
the flow sorting method.
Studies have found that tumor stem cells have pheno-
typic stability, which means in addition to differentiating
into most of the mature tumor cells; they can also gener-
ate new tumor stem cells, which owns the same markers
as the primary tumor stem cells and is the source of
tumor recurrence and metastasis [22,6]. This experiment
was designed based on its phenotypic stability. Ovarian
cancer cells were sorted according to different expressions
of negative and positive CA125 by using a flow cytometry,
and then cells were orthotopically implanted into the
Figure 13 The expressions of human CA125 (red light) and
mouse antigen (green light) of the ovarian tumor.
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tumor cells with different markers; the tumor cells were
digested and suspended, followed by being labeled with
antibodies and undergoing mouse passage for observing
tumorigenicity, so as to confirm the relation of ovarian
tumor stem cells and CA125 and to find their specific
markers. This study provides theoretical and experimental
basis for specifically killing ovarian tumor stem cells and
preventing tumor recurrence.
In this experiment, we preliminary identified the rela-
tionship between tumor marker CA125 and ovarian
cancer stem cells, and obtained satisfactory results The
second antibody labeled by monoclonal antibody of
CA125 (OC125) and APC was used to isolate tumor
cells with CA125 expression, and lineage-specific anti-
bodies labeled by PE, FITC and other fluorescence were
used to eliminate human normal cells in the tumor tis-
sues; PI was used to eliminate dead cells. Accurate sort-
ing can be obtained by using flow cytometry since APC,
FITC, PE, and PI are 4 different colors of fluorescence.
The tumor cells without human normal cells and dead
cells were divided into a negative cell group and a posi-
tive cell group according to CA125 expression, and they
were orthotopically implanted into ovaries of SCID mice
with same cell magnitude to compare tumorigenicity of
different tumor cells. We found that there were 8 tumors
in the positive groups, while there were no tumors in the
negative and control groups; the difference was statically
significant, indicating that tumor marker CA125 may be
one of the marker for ovarian tumor stem cells. Further
confirmations will be the focus of our future studies by in-
creasing magnitude in the number of subjects, as well asadding additional tumor markers. Finding the tumor
marker for ovarian cancer prompts the targeting or se-
lective killing these “seed cells”, and enables tumor cure,
preventing recurrence and metastasis of tumors.
In 1981, Robert et al. [18] found antigen CA125 in the
ovarian cancer cells by using monoclonal antibody OC125.
Since then, CA125 has been an auxiliary diagnostic marker
for ovarian cancer, and research about immunological
treatment of ovarian cancer using the antibody’s specificity
for CA125 is also emerging. Our experiments showed that
CA125 may be one of the surface markers of tumor stem
cells, and further studies are needed to investigate the ex-
istence of other markers, which is the direction of our fu-
ture studies. Finding the markers of ovarian cancer stem
cells and targeting killing these “seed cells”, making the
prevention and treatment of ovarian cancer possible.
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